Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Therapies for Autoimmune Diseases
April 3, 2023
Sonoma Biotherapeutics is to receive $75 million upfront, inclusive of $45 million cash and $30 million equity investment; with the potential for an additional $45 million development milestone payment.
Sonoma Bio was founded by Jeff Bluestone, PhD, and Qizhi Tang, PhD, both UCSF researchers.